While You Were Waiting For Praluent, FDA Approved Four Other Drugs
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA clears AbbVie’s Technivie, Novartis’ Odomzo, a new indication for Amgen’s Kyprolis and Bristol’s Daklinza July 24 before its much anticipated approval of Regeneron/Sanofi’s Praluent.